-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 25, Renhe Pharmaceutical announced that its subsidiary Jiangxi Pharmaceutical has recently received the "Drug Registration Certificate" for Entecavir tablets approved and issued by the State Drug Administration.
Product entecavir indications: This product is suitable for active viral replication, serum alanine aminotransferase (ALT) continues to rise, or liver histology showed chronic active lesions of adult hepatitis B treatment (including generation of compensation and Patients with liver disease in decompensated stage).
(ALT) continues to rise or liver histology showed active lesions in the treatment of chronic hepatitis B in adults (including the generation of compensation and patients with decompensated liver disease).
country).
As of the date of this announcement, the accumulated research and development expenses of Entecavir tablets are approximately RMB 8,127,200.